Table 1.
Number of cows, average ± standard deviation of anti-F. hepatica antibody levels before treatment and 305-day milk production in the lactation before treatment and distribution of breed, parity and year quarter of treatment in the 2 treatment groups.
Figure 1.
The course of anti-F. hepatica antibody levels (ODR) during the study period in bulk-tank milk samples from the 12 studied herds (A) and relative to the months after experimental treatment in individual milk samples of 475 cows in the 12 herds (B).
Bars represent standard error of the mean.
Figure 2.
The average lactation curve of cows following treatment with closantel or a placebo at dry-off (Curves represent the data for Holstein Friesian cows in ≥3rd lactation).
Table 2.
The results of a linear mixed model to estimate the effect of closantel treatment at dry-off (or approximately 42 days before calving for heifers) on 305-day milk production in 11 herds exposed to F. hepatica (based on 402 cows).
Table 3.
Least square meansa (standard error of the mean) of average protein and fat concentration and milk production parameters following treatment in the closantel and placebo group.
Figure 3.
The estimated effect of closantel treatment at dry-off (or approximately 42 days before calving for heifers) on 305-day milk production according to several potential decision parameters for selective anthelmintic treatment.
Error bars represent the 95%-confidence interval of the treatment-effect. Categories for F. hepatica ELISA results and body condition score represent quartiles.